Status: Not yet recruiting
A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol
The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a breast cancer resistant protein substrate) in healthy male participants.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18-55Biological sex: MaleType: InterventionalSponsor: Chiesi Farmaceutici S.p.A.Updated: Aug 4, 2026Locations: 1
Eligibility criteria
Healthy male participants aged 18 to 55 years [+5]
Use of prohibited concomitant medications [+8]